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when the stage of disease was matched.7,8) Diagnosis and
management of PABC are additional challenge for a
clinician because not only the treatment of pregnant
woman herself but also the safety of the fetus should be
considered. There are many issues to be determined
regarding pregnancy and breast cancer in younger
women.
The aims of this study were to investigate
clinicopathological characteristics and outcomes of PABC
compared to those of invasive breast cancer patients aged
less than 40 years, and to evaluate whether pregnancy
itself is an independent prognostic factor and whether the
survival of the patients diagnosed before and after their
delivery is different among younger Korean breast cancer
patients in association with PABC.
PATIENTS AND METHODS
Study population
Patients were selected from the Yonsei Hospital Breast
Cancer Registry Database containing clinicopathological
information, treatment modalities, and details of outcomes.
A total of 1,106 patients under 40 years of age were treated
for breast cancer at the Department of Surgery, Yonsei
University College of Medicine, Seoul, Korea, between
January 1987 and December 2007, and the exclusion criteria
were as follows (n=237): pure in situ breast carcinoma,
recurrent or metastatic disease, non-PABC patients with
special histological types including lobular carcinoma, and
tumors of non-epithelial origin  such as phyllodes tumor,
lymphoma, or sarcoma. PABC was defined as breast cancer
diagnosed during pregnancy or during the first postpartum
year. A total of 14 patients fulfilled the above criteria.
Clinicopathological characteristics, treatment patterns, and
survival outcomes were compared to those of 855 invasive
ductal carcinoma not otherwise specified (IDC) patients less
than 40 years of age.
Patients were treated with either total mastectomy or
breast-conserving surgery and sentinel lymph node biopsy
or axillary lymph node dissection. Sentinel lymph node
was detected using radioisotope technique with 18.5 MBq
(0.5 mCi) 99mTc Phytate Kit (Korea Atomic Energy Research
Institute, Daejeon, Korea). After surgery, local
radiotherapy or adjuvant systemic treatment was
conducted if the patient was able to tolerable it. Among
the whole study population, 95 (10.9%) patients with locally
advanced breast cancer received preoperative
chemotherapy containing anthracycline with or without
taxane regimen. Clinical follow-up included history
taking, physical examination, laboratory tests, and
radiological imaging tests every 6-12 months for detection
of relapse. Tumor stage was based on the American Joint
Committee on Cancer staging criteria (6th edition).
Histological grade was assessed by the modified Bloom-
Richardson classification. Tumors with ≥ 10% nuclear-
stained cells were considered positive for estrogen (ER) and
progesterone receptors (PR). HER2/neu immunohistochemical
staining was scored from 0 to 3+ according to the
guidelines for the HercepTestTM (Dako, Glostrup,
Denmark).9) Because fluorescence in situ hybridization
(FISH) test had not been performed routinely during most
of the study period, HER-2 staining was considered
positive when strong (3+) membrane staining was
observed, whereas cases from 0 to 2+ were regarded as
negative.
Study endpoints and statistics
Locoregional recurrence was defined as tumor recurrence
in the ipsilateral breast, chest wall, and regional lymph
node. Any recurrence at a distant site including
contralateral axillary or supraclavicular lymph nodes was
considered as a distant metastasis. Disease-free survival
(DFS) was measured from the date of the first curative
surgery to the date of the first locoregional or systemic
recurrence, or death before any type of relapse.
Locoregional relapse-free survival (LRRFS) was calculated
from the date of the first operation to the date of the first
locoregional relapse or death without any type of
recurrence. Distant relapse-free survival (DRFS) was
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초 록
목적 : 본연구는임신성유방암의임상병리학적특징과예후를조
사하여임신이임신성유방암에미치는 향을평가하고자하 다. 
방법 : 1987년부터2007년사이에치료받은 14명의임신성유방암
환자들의임상병리적특성, 치료방법, 생존율을855명의40세미만
침윤성유방암환자들과chi-square 검정, Kaplan-Meier 방법, 그
리고Cox’s hazards 모델을이용하여비교하 다. 임신성유방암은
임신기간중또는출산후1년이내에진단된유방암으로정의하 다. 
결과 : 14명의임신성유방암환자중, 7명은임신중에진단되었으
며, 7명은산후1년내에진단되었다. 평균증상기간은7.6개월이었
고, 임신성유방암과40세미만유방암환자들의평균나이는각각
32.6세, 34.6세 다(p=0.044). 임신성유방암은모두유관암이었으
며, 병기, 호르몬수용체발현, 치료방법은임신성유방암과40세미
만유방암사이에통계적차이를보이지않았다. 임신성유방암환자
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INTRODUCTION
In Korea, the incidence of breast cancer has been
increasing significantly in recent years and the absolute
number of young breast cancer patients less than 40 years
of age has also been increasing.1) Pregnancy and breast
cancer have become a significant concern for not only
young women but also clinicians. Breast cancer is the most
commonly diagnosed malignancy during pregnancy.2) The
incidence has been reported to be from 1:3,000 to 1:10,000
pregnancies and from 0.2% to 3.8% of breast cancer
patients whose age was less than 50 years.3,4) Pregnancy-
associated breast cancer (PABC) is generally defined as
breast cancer diagnosed during pregnancy or within the
first year after delivery. Recent trends in delaying
childbearing may elicit a further increase in the incidence
of PABC.
Traditionally pregnancy has been considered to decrease a
woman’s lifetime risk of developing breast cancer, but
more detailed analyses suggest that pregnancy itself
transiently increases the risk of breast cancer.3,5) Delay in
diagnosis of breast cancer during pregnancy, promotional
effects of gestational hormones on tumor, and
undetermined aggressive intrinsic tumor biology of PABC
make pregnant women with breast cancer presenting with
more advanced stage breast cancer, and subsequently
show a poorer prognosis.5,6) On the contrary, it has been
reported that the survival of PABC patients is not
significantly different from that of non-PABC patients
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guidelines for the HercepTestTM (Dako, Glostrup,
Denmark).9) Because fluorescence in situ hybridization
(FISH) test had not been performed routinely during most
of the study period, HER-2 staining was considered
positive when strong (3+) membrane staining was
observed, whereas cases from 0 to 2+ were regarded as
negative.
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carcinoma without lobular or special type. Tumor and node
stage was not significantly different between PABC and
IDC under 40 years of age. Among the patients with
PABC, 11 (78.6%) were in stage II, 2 (14.3%) in stage I, and 1
(7.1%) in stage III, respectively. No significant difference in
histological grade was found between two groups. Among
the patients who were available for ER (n=720) and PR
(n=706), PABC subgroup showed higher frequency of ER-
and PR-negative tumor, but there was no statistical
significance. The patients with PABC were determined to
present higher proportion of HER2-positive tumor.
However, too many missing values and no FISH analysis
make our results subject to be validated using independent
dataset.
Treatment modalities of the patients with PABC were
compared to those of IDC under 40 years of age (Table 2).
Three patients with PABC received neoadjuvant
chemotherapy using FAC (fluorouracil, anthracycline, and
cyclophosphamide) or AT (anthracycline and taxane)
regimens. Seven patients with PABC underwent breast-
conserving surgery. Sentinel lymph node biopsy using
radioisotope and subsequent axillary node dissection were
performed in four patients with PABC. Among them, two
patients were in the third trimester of pregnancy. After
breast surgery with sentinel node biopsy, they delivered a
healthy baby. There was no significant difference of
treatment patterns including systemic chemotherapy or
endocrine therapy between PABC and IDC under 40 years
of age.
The Kaplan-Meier curves for DFS, LRRFS, DRFS, and OS
are demonstrated in Fig. 1. Five-year DFS, LRRFS, DRFS,
and OS of the patients with PABC was 57.1%, 71.3%,
56.4%, and 70.0%, respectively. Survival between PABC
and IDC under 40 years of age was not significantly
different. In the Cox’s regression models adjusting for age
at diagnosis, tumor and node stage, grade, ER, and the
use of chemotherapy and endocrine therapy, PABC was
not associated with survival outcomes (Table 3). Age at
diagnosis, tumor stage, node status, and the use of
chemotherapy were determined to be independent
measured from the date of the first operation to the date
of the first distant metastasis or death without any type of
recurrence. Overall survival (OS) was calculated from the
date of the first surgery to the date of the last follow-up
or death from any cause.
The differences between the groups were evaluated by a
chi-square test. Fisher’s exact test was used when
appropriate. Continuous variable was compared using
two-sample t-test. Survival curve was plotted using the
Kaplan-Meier method and group differences in survival
times were investigated by a log-rank test. A Cox’s
proportional hazards model was used to identify the
variables that were independently associated with
survival. All statistical tests were two-sided and a p-value
<0.05 was considered statistically significant. SPSS for
Windows version 18.0 (SPSS Inc., Chicago, IL) was used for
all statistical analysis.
RESULTS
During the study period, 14 patients were diagnosed with
PABC, which constituted 0.3% of all 4,335  IDC patients
treated at our institution irrespective of age at diagnosis,
0.6% of 2,541 IDC patients aged less than 50 years, and
1.6% of 869 IDC patients under 40 years. The mean age of
the whole study population at diagnosis was 34.6 years
[standard deviation (SD), 3.8]. The mean follow-up
duration was 69.4 months (SD, 45). Among 14 patients
with PABC, 7 were diagnosed with breast cancer during
pregnancy: 3 were in the first trimester of pregnancy and
4 in the third trimester. The 7 rest of the patients (7 of 14
patients) were diagnosed with breast cancer during
postpartum period. Thirteen patients showed a chief
complaint of breast lump and bloody nipple discharge
present in one patient. The mean symptom duration was
7.6 months (SD, 7.7; range 0.5-24) in 14 patients with
PABC. The mean symptom duration of the patients
diagnosed during pregnancy and during postpartum period
was 4.5 and 10.7 months, respectively. However, there was
no statistical significance (p=0.143, two-sample t-test).
The mean tumor size of the patients diagnosed during
pregnancy and during postpartum period was 3.0cm (SD,
1.3) and 2.3cm (SD, 1.2), respectively, which was not
significantly different (p=0.331, t-test). Three patients
diagnosed during the first trimester underwent
therapeutic abortion with simultaneous treatment of
breast cancer.
Comparison of clinicopathological characteristics between
PABC and IDC under 40 years of age is shown in Table 1.
The mean age at diagnosis of PABC and IDC under 40
years of age was 32.6 (range, 24-39) and 34.6 (range, 20-
39) years, respectively. The patients with PABC were
younger at diagnosis than those with IDC less than 40
years old (p=0.044, t-test). All PABCs were ductal
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Factor PABC




Mean±SD (range) 32.6 (24-39) 34.6 (20-39) 0.044*
<35 9 (64.3) 338 (39.5) 0.061
35~39 5 (35.7) 517 (60.5)
Tumor size
≤ 2cm 6 (42.9) 369 (43.2) 0.982
> 2cm 8 (57.1) 486 (56.8)
Node stage
N0 9 (64.3) 431 (50.4) 0.739†
N1 4 (28.6) 257 (30.1)
N2 0 (0.0) 84 (9.8)
N3 1 (7.1) 83 (9.7)
Histologic grade (n=649)
I 3 (27.3) 116 (18.2) 0.541†
II 5 (45.5) 355 (55.6)
III 3 (27.3) 167 (26.2)
Estrogen receptor (n=720)
Negative 6 (50.0) 286 (40.4) 0.560†
Positive 6 (50.0) 422 (59.6)
Progesterone receptor (n=706)
Negative 7 (58.3) 294 (42.4) 0.267
Positive 5 (41.7) 400 (57.6)
HER2 (n=496)
Negative 5 (55.6) 372 (76.4) 0.228†
Positive 4 (44.4) 115 (23.6)
Table 1. Clinicopathological Characteristics
*Two-sample t-test; †Fisher’s exact test.
Abbreviations: PABC, pregnancy-associated breast cancer; IDC, invasive ductal carcinoma;
SD, standard deviation; HER2, human epidermal growth factor receptor 2.
Factor PABC




Not done 11 (78.6) 763 (89.2) 0.190*
Done 3 (21.4) 92 (10.8)
Type of surgery
Breast-conserving surgery 7 (50.0) 225 (26.3) 0.064*
Total mastectomy 7 (50.0) 630 (73.7)
Radiotherapy (n=835)
Not done 5 (35.7) 457 (55.7) 0.137
Done 9 (64.3) 364 (44.3)
Chemotherapy (n=860)
Not done 2 (14.3) 116 (13.7) >0.999*
Done 12 (85.7) 730 (86.3)
Endocrine therapy (n=836)
Not done 8 (57.1) 449 (54.6) 0.851
Done 6 (42.9) 373 (45.4)
Table 2. Treatment Patterns
*Fisher’s exact test
Abbreviations: PABC, pregnancy-associated breast cancer; IDC, invasive ductal carcinoma.
Fig. 1. Disease-free (A), locoregional relapse-free (B), distant
relapse-free (C), and overall (D) survival curve. 
Solid line represents pregnancy-associated breast cancer and dotted line
represents invasive ductal carcinoma less than 40 years of age.
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significantly different (p=0.331, t-test). Three patients
diagnosed during the first trimester underwent
therapeutic abortion with simultaneous treatment of
breast cancer.
Comparison of clinicopathological characteristics between
PABC and IDC under 40 years of age is shown in Table 1.
The mean age at diagnosis of PABC and IDC under 40
years of age was 32.6 (range, 24-39) and 34.6 (range, 20-
39) years, respectively. The patients with PABC were
younger at diagnosis than those with IDC less than 40
years old (p=0.044, t-test). All PABCs were ductal
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Factor PABC




Mean±SD (range) 32.6 (24-39) 34.6 (20-39) 0.044*
<35 9 (64.3) 338 (39.5) 0.061
35~39 5 (35.7) 517 (60.5)
Tumor size
≤ 2cm 6 (42.9) 369 (43.2) 0.982
> 2cm 8 (57.1) 486 (56.8)
Node stage
N0 9 (64.3) 431 (50.4) 0.739†
N1 4 (28.6) 257 (30.1)
N2 0 (0.0) 84 (9.8)
N3 1 (7.1) 83 (9.7)
Histologic grade (n=649)
I 3 (27.3) 116 (18.2) 0.541†
II 5 (45.5) 355 (55.6)
III 3 (27.3) 167 (26.2)
Estrogen receptor (n=720)
Negative 6 (50.0) 286 (40.4) 0.560†
Positive 6 (50.0) 422 (59.6)
Progesterone receptor (n=706)
Negative 7 (58.3) 294 (42.4) 0.267
Positive 5 (41.7) 400 (57.6)
HER2 (n=496)
Negative 5 (55.6) 372 (76.4) 0.228†
Positive 4 (44.4) 115 (23.6)
Table 1. Clinicopathological Characteristics
*Two-sample t-test; †Fisher’s exact test.
Abbreviations: PABC, pregnancy-associated breast cancer; IDC, invasive ductal carcinoma;
SD, standard deviation; HER2, human epidermal growth factor receptor 2.
Factor PABC




Not done 11 (78.6) 763 (89.2) 0.190*
Done 3 (21.4) 92 (10.8)
Type of surgery
Breast-conserving surgery 7 (50.0) 225 (26.3) 0.064*
Total mastectomy 7 (50.0) 630 (73.7)
Radiotherapy (n=835)
Not done 5 (35.7) 457 (55.7) 0.137
Done 9 (64.3) 364 (44.3)
Chemotherapy (n=860)
Not done 2 (14.3) 116 (13.7) >0.999*
Done 12 (85.7) 730 (86.3)
Endocrine therapy (n=836)
Not done 8 (57.1) 449 (54.6) 0.851
Done 6 (42.9) 373 (45.4)
Table 2. Treatment Patterns
*Fisher’s exact test
Abbreviations: PABC, pregnancy-associated breast cancer; IDC, invasive ductal carcinoma.
Fig. 1. Disease-free (A), locoregional relapse-free (B), distant
relapse-free (C), and overall (D) survival curve. 
Solid line represents pregnancy-associated breast cancer and dotted line
represents invasive ductal carcinoma less than 40 years of age.
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and IDC under 40 years of age.
Under general anesthesia, breast surgery can be safely
performed with little risk to the fetus during any stage of
pregnancy.3) Patients with PABC can be treated with
mastectomy or breast-conserving surgery. Elective
abortion has been found not to improve survival for PABC
patients.14) Therefore, it is not routinely recommended as a
therapeutic approach but should be discussed in case of
the early pregnancy period. Radiation therapy is
contraindicated during pregnancy due to the increased risk
of teratogenesis. However, radiation therapy can be
delayed up to 12 weeks without increasing the risk of local
recurrence and if adjuvant or neoadjuvant chemotherapy
is indicated according to the risk evaluation, the delay in
breast irradiation up to 6 months may be possible.8)
Recently, the international panel of experts have
recommended that even if patients are treated in the first
trimester or early second trimester, radiation therapy can
be delayed until after delivery, but local failure rate of
PABC patients treated with breast-conserving therapy is
not clearly defined.2) Axillary staging by sentinel lymph
node biopsy using 99m-Tc is determined to be safe and
accurate in the pregnant women with clinically node-
negative disease.15) However, the use of blue dye is not
recommended because of anaphylaxis, teratogenesis, or
unknwn effects to the fetus.3,8)
The decision to administer systemic chemotherapy in a
PABC patient should depend on the risk evaluation such as
disease stage and clinicopathological features as in a non-
pregnant breast cancer patient.16) Although most
chemotherapeutic agents are under the U.S. Food and
Drug Administration pregnancy FDA category D, namely
positive evidence of human fetal risk exists but benefits in
certain situations may make use of the acceptable drug
despite its risk. Several recent studies have shown that
certain chemotherapy regimens including anthracycline
can be safely used during the second and third trimester of
pregnancy.3,16,17) PABC patients should not receive any
chemotherapeutic drugs for at least three weeks prior to
delivery to allow for correction of myelosuppression in
both the mother and fetus.3) Antiemetic agents such as
ondansetron (ZofranⓇ) and granisetron (KytrilⓇ) are rated
pregnancy risk category B and are safely used in pregnant
women receiving chemotherapy.16) The short use of
dexamethasone for nausea prophylaxis and granulocyte
colony-stimulating factor (G-CSF) for neutropenia
prophylaxis also can be available.10,16,17) Endocrine therapy
using tamoxifen should be initiated after delivery and
completion of chemotherapy if PABC is determined as
endocrine-responsive tumor. Although no fetal
abnormalities has been described, some cases of
anhydramnios or oligohydramnios, which is known to
significantly increase the risk of premature delivery, fetal
morbidity, and mortality, have been reported by the use of
trastuzumab during pregnancy.18.19) The safety profile of
trastuzumab or lapatinib during pregnancy is supported by
very limited data, so, targeted agents are not routinely
recommended yet.10,19)
It has not been clearly established whether pregnancy
itself is an independent predictor for outcomes in PABC.
The prognosis of PABC had been known to be poor, partly
associated with the delay in diagnosis and treatment,
higher stage at diagnosis, more favorable microenvironment
created during pregnancy, and BRCA1 and BRCA2
germline mutations.6,20,21) Except for only two patients, our
PABC subgroups were diagnosed with stage II disease,
although there was no statistical difference between the
two groups. However, when pregnant women are age and
stage-matched with non-pregnant controls, survival is
determined to be equivalent between the two groups.3,22)
This is further supported by our results of no difference in
DFS, LRRFS, DRFS, and OS between PABC and IDC less
than 40 years of age.
Recently a large population-based study of Swedish
women with PABC showed that the elevated mortality
among PABC patients varied markedly with timing of
diagnosis in relation to delivery.23) The authors observed
nearly 4 times higher peak mortality in women diagnosed
Pregnancy-Associated Breast Cancer Compared to Invasive Ductal Carcinoma Less Than 40 Year-Old of Age
prognostic factors in our study population of young breast
cancer patients. Among the patients with PABC, there was
no statistical difference in survival outcomes between the
patients diagnosed before and after delivery (Fig. 2).
DISCUSSION
The majority of abnormal breast findings during
pregnancy or lactation are benign disease including
infectious complications. It has been widely recognized
that the delay in diagnosis is associated with more
advanced disease at diagnosis of women with PABC.10)
Therefore, physicians should be vigilant of any suspicious
abnormalities during pregnancy or lactation to avoid a
delay in the diagnosis of breast cancer. It has been
reported that the average age of patients with PABC is
32-38 years and the average delay in diagnosis in
pregnant patients is 5-10 months as compared to 1-4
months in non-pregnant patients.3) Our mean age at
diagnosis and average symptom duration of the patients
with PABC was 32.6 years and 7.6 months. In 2006, The
Korean Breast Cancer Society reported that 64.5% of
newly diagnosed breast cancer patients presented
symptom duration of less than 3 months and 15.8%
presented symptom duration of 3 to 6 months.11) These
findings suggest that diagnosis of Korean PABC might be
delayed similar to the western series.
IDC is the most prevalent histological type of cancer in
PABC and these tumors tend to have higher grade and
lymphovascular invasion.3,12) PABC shows typically
frequent and larger size axillary node metastasis.13)
Gestational hormones may play an important role for
aggressive biology of PABC.6) A higher percentage of PABC
is ER- and/or PR-negative tumor and increased
overexpression of HER2 is also common.8) PABC frequently
presents higher Ki-67 proliferative index.13) However, the
majority of these studies are composed of case series with
small sample size. The overall histopathological and
immunohistochemical findings of PABC are consistent
with young patients with breast cancer.8) In our study,
histopathological characteristics and expression of
biomarkers are not significantly different between PABC
32 Ban Seok Yang•Seho Park•So Hee Lee•Hyung Seok Park•Hyewon Hwang•Jun Sang Lee•Si Mon Ko•Seung Il Kim•Byeong-Woo Park
DFS LRRFS DRFS OS
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Pregnancy-associated (yes) 1.604 0.584-4.402 0.359 1.289 0.404-4.115 0.668 1.924 0.697-5.314 0.207 1.881 0.581-6.091 0.292
Age (< 35 yrs) 1.696 1.255-2.292 0.001 1.706 1.230-2.367 0.001 1.671 1.214-2.301 0.002 1.741 1.203-2.517 0.003
Tumor size (> 2cm) 1.752 1.252-2.452 0.001 1.708 1.175-2.483 0.005 1.876 1.303-2.699 0.001 1.718 1.121-2.633 0.013
Node status (positive) 2.805 1.973-3.987 <0.001 2.799 1.885-4.156 <0.001 2.984 2.045-4.353 <0.001 3.302 2.070-5.267 <0.001
Grade (II/III) 1.138 0.754-1.719 0.537 1.254 0.785-2.003 0.343 1.244 0.792-1.953 0.344 1.552 0.886-2.717 0.124
ER (negative) 0.909 0.603-1.369 0.647 0.923 0.595-1.434 0.723 0.960 0.622-1.480 0.852 0.898 0.551-1.465 0.668
Chemotherapy (not done) 2.485 1.313-4.704 0.005 2.885 1.458-5.710 0.002 1.858 0.851-4.059 0.120 2.374 0.994-5.672 0.052
Endocrine therapy (not done) 1.216 0.822-1.799 0.327 1.418 0.920-2.186 0.114 1.121 0.740-1.696 0.591 1.486 0.916-2.411 0.109
Table 3. Multivariate Analyses for Survival
Abbreviations: DFS, disease-free survival; LRRFS, locoregional relapse-free survival; DRFS, distant relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ER,
estrogen receptor.
Fig. 2. Disease-free (A) and overall (B) survival of the patients
diagnosed before and after delivery.
Solid line represents breast cancer patients diagnosed during antepartum
period and dotted line represents those diagnosed during postpartum period.
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and IDC under 40 years of age.
Under general anesthesia, breast surgery can be safely
performed with little risk to the fetus during any stage of
pregnancy.3) Patients with PABC can be treated with
mastectomy or breast-conserving surgery. Elective
abortion has been found not to improve survival for PABC
patients.14) Therefore, it is not routinely recommended as a
therapeutic approach but should be discussed in case of
the early pregnancy period. Radiation therapy is
contraindicated during pregnancy due to the increased risk
of teratogenesis. However, radiation therapy can be
delayed up to 12 weeks without increasing the risk of local
recurrence and if adjuvant or neoadjuvant chemotherapy
is indicated according to the risk evaluation, the delay in
breast irradiation up to 6 months may be possible.8)
Recently, the international panel of experts have
recommended that even if patients are treated in the first
trimester or early second trimester, radiation therapy can
be delayed until after delivery, but local failure rate of
PABC patients treated with breast-conserving therapy is
not clearly defined.2) Axillary staging by sentinel lymph
node biopsy using 99m-Tc is determined to be safe and
accurate in the pregnant women with clinically node-
negative disease.15) However, the use of blue dye is not
recommended because of anaphylaxis, teratogenesis, or
unknwn effects to the fetus.3,8)
The decision to administer systemic chemotherapy in a
PABC patient should depend on the risk evaluation such as
disease stage and clinicopathological features as in a non-
pregnant breast cancer patient.16) Although most
chemotherapeutic agents are under the U.S. Food and
Drug Administration pregnancy FDA category D, namely
positive evidence of human fetal risk exists but benefits in
certain situations may make use of the acceptable drug
despite its risk. Several recent studies have shown that
certain chemotherapy regimens including anthracycline
can be safely used during the second and third trimester of
pregnancy.3,16,17) PABC patients should not receive any
chemotherapeutic drugs for at least three weeks prior to
delivery to allow for correction of myelosuppression in
both the mother and fetus.3) Antiemetic agents such as
ondansetron (ZofranⓇ) and granisetron (KytrilⓇ) are rated
pregnancy risk category B and are safely used in pregnant
women receiving chemotherapy.16) The short use of
dexamethasone for nausea prophylaxis and granulocyte
colony-stimulating factor (G-CSF) for neutropenia
prophylaxis also can be available.10,16,17) Endocrine therapy
using tamoxifen should be initiated after delivery and
completion of chemotherapy if PABC is determined as
endocrine-responsive tumor. Although no fetal
abnormalities has been described, some cases of
anhydramnios or oligohydramnios, which is known to
significantly increase the risk of premature delivery, fetal
morbidity, and mortality, have been reported by the use of
trastuzumab during pregnancy.18.19) The safety profile of
trastuzumab or lapatinib during pregnancy is supported by
very limited data, so, targeted agents are not routinely
recommended yet.10,19)
It has not been clearly established whether pregnancy
itself is an independent predictor for outcomes in PABC.
The prognosis of PABC had been known to be poor, partly
associated with the delay in diagnosis and treatment,
higher stage at diagnosis, more favorable microenvironment
created during pregnancy, and BRCA1 and BRCA2
germline mutations.6,20,21) Except for only two patients, our
PABC subgroups were diagnosed with stage II disease,
although there was no statistical difference between the
two groups. However, when pregnant women are age and
stage-matched with non-pregnant controls, survival is
determined to be equivalent between the two groups.3,22)
This is further supported by our results of no difference in
DFS, LRRFS, DRFS, and OS between PABC and IDC less
than 40 years of age.
Recently a large population-based study of Swedish
women with PABC showed that the elevated mortality
among PABC patients varied markedly with timing of
diagnosis in relation to delivery.23) The authors observed
nearly 4 times higher peak mortality in women diagnosed
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prognostic factors in our study population of young breast
cancer patients. Among the patients with PABC, there was
no statistical difference in survival outcomes between the
patients diagnosed before and after delivery (Fig. 2).
DISCUSSION
The majority of abnormal breast findings during
pregnancy or lactation are benign disease including
infectious complications. It has been widely recognized
that the delay in diagnosis is associated with more
advanced disease at diagnosis of women with PABC.10)
Therefore, physicians should be vigilant of any suspicious
abnormalities during pregnancy or lactation to avoid a
delay in the diagnosis of breast cancer. It has been
reported that the average age of patients with PABC is
32-38 years and the average delay in diagnosis in
pregnant patients is 5-10 months as compared to 1-4
months in non-pregnant patients.3) Our mean age at
diagnosis and average symptom duration of the patients
with PABC was 32.6 years and 7.6 months. In 2006, The
Korean Breast Cancer Society reported that 64.5% of
newly diagnosed breast cancer patients presented
symptom duration of less than 3 months and 15.8%
presented symptom duration of 3 to 6 months.11) These
findings suggest that diagnosis of Korean PABC might be
delayed similar to the western series.
IDC is the most prevalent histological type of cancer in
PABC and these tumors tend to have higher grade and
lymphovascular invasion.3,12) PABC shows typically
frequent and larger size axillary node metastasis.13)
Gestational hormones may play an important role for
aggressive biology of PABC.6) A higher percentage of PABC
is ER- and/or PR-negative tumor and increased
overexpression of HER2 is also common.8) PABC frequently
presents higher Ki-67 proliferative index.13) However, the
majority of these studies are composed of case series with
small sample size. The overall histopathological and
immunohistochemical findings of PABC are consistent
with young patients with breast cancer.8) In our study,
histopathological characteristics and expression of
biomarkers are not significantly different between PABC
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HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Pregnancy-associated (yes) 1.604 0.584-4.402 0.359 1.289 0.404-4.115 0.668 1.924 0.697-5.314 0.207 1.881 0.581-6.091 0.292
Age (< 35 yrs) 1.696 1.255-2.292 0.001 1.706 1.230-2.367 0.001 1.671 1.214-2.301 0.002 1.741 1.203-2.517 0.003
Tumor size (> 2cm) 1.752 1.252-2.452 0.001 1.708 1.175-2.483 0.005 1.876 1.303-2.699 0.001 1.718 1.121-2.633 0.013
Node status (positive) 2.805 1.973-3.987 <0.001 2.799 1.885-4.156 <0.001 2.984 2.045-4.353 <0.001 3.302 2.070-5.267 <0.001
Grade (II/III) 1.138 0.754-1.719 0.537 1.254 0.785-2.003 0.343 1.244 0.792-1.953 0.344 1.552 0.886-2.717 0.124
ER (negative) 0.909 0.603-1.369 0.647 0.923 0.595-1.434 0.723 0.960 0.622-1.480 0.852 0.898 0.551-1.465 0.668
Chemotherapy (not done) 2.485 1.313-4.704 0.005 2.885 1.458-5.710 0.002 1.858 0.851-4.059 0.120 2.374 0.994-5.672 0.052
Endocrine therapy (not done) 1.216 0.822-1.799 0.327 1.418 0.920-2.186 0.114 1.121 0.740-1.696 0.591 1.486 0.916-2.411 0.109
Table 3. Multivariate Analyses for Survival
Abbreviations: DFS, disease-free survival; LRRFS, locoregional relapse-free survival; DRFS, distant relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ER,
estrogen receptor.
Fig. 2. Disease-free (A) and overall (B) survival of the patients
diagnosed before and after delivery.
Solid line represents breast cancer patients diagnosed during antepartum
period and dotted line represents those diagnosed during postpartum period.
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Pregnancy-Associated Breast Cancer Compared to Invasive Ductal Carcinoma Less Than 40 Year-Old of Age
with breast cancer during 4-6 months after delivery and
subsequent higher mortality rate in women diagnosed
during pregnancy or within 3 months after birth. Since the
involution of breast to its pre-pregnant state begins to
occur during those periods, they suggest the hypothesis
that postpartum changes in the microenvironment of
mammary gland may enhance tumor growth and
metastasis.23,24) Although small sample size of our PABC
subgroup could not come to solid conclusions, there was no
statistical difference in survival outcomes between women
diagnosed with breast cancer before and after delivery. It
is remained to be determined in the near future.
In conclusion, PABC patients frequently presented breast
symptoms such as palpable lump and showed longer
symptom duration. Clinicopathological characteristics,
treatment patterns, and survival outcomes were not
significantly different between PABC and IDC less than 40
years of age. Pregnancy itself did not increase the risk of
poorer disease outcome when adjusting for other
clinicopathological parameters. Therefore, pregnant or
lactating women who present breast symptoms should be
urgently evaluated as not to delay the diagnosis and be
treated appropriately with multidisciplinary therapeutic
modalities once an accurate diagnosis is made. Termination
of pregnancy should be discussed along with the
implications of pregnancy when dealing with the choice of
treatment options, the possible effects on the fetus and the
prognosis. Since pregnant or lactating women have been
excluded in most prospective clinical trials, ethically
supported new randomized trials and basic researches for
the biological mechanisms of pregnancy should be
developed to determine issues that remain unsettled.
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urgently evaluated as not to delay the diagnosis and be
treated appropriately with multidisciplinary therapeutic
modalities once an accurate diagnosis is made. Termination
of pregnancy should be discussed along with the
implications of pregnancy when dealing with the choice of
treatment options, the possible effects on the fetus and the
prognosis. Since pregnant or lactating women have been
excluded in most prospective clinical trials, ethically
supported new randomized trials and basic researches for
the biological mechanisms of pregnancy should be
developed to determine issues that remain unsettled.
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Introduction
Laparoscopic colectomy was introduced by Jacobs et al. in
1991.(1) Since then, many studies reported the benefits and
oncologic outcomes of laparoscopic colorectal surgery.(2-5) In
recent years, laparoscopic surgery has been considered as
one of the surgical options for colorectal cancer.(6) The
application of laparoscopic techniques in colorectal surgery
has widened.
The well known advantages of laparoscopy are rapid
postoperative recovery, small surgical wound, less
postoperative pain, shorter hospital stay, and so on.(1,4,7-10)
On the other hand, the widely known disadvantages of
laparoscopic surgery are longer operating times, steep
learning curve, and the lack of tactile sense.(1,4,8-11)
Moreover, oncologic outcomes of laparoscopic surgery
especially for rectal cancer remain to be verified. 
Pneumoperitoneum is necessary for laparoscopic surgery
to get an adequate operative field, and frequently,
exaggerated patient’s positions are also required. These
have been reported to influence the cardio-pulmonary and
renal functions. The elderly colorectal cancer patients tend
to have more comorbidity. The physiologic burdens of
pneumoperitoneum and other factors during laparoscopic
surgery may be disadvantageous to elderly patients,
theoretically, and there is a possibility of harmful effects
in the elderly compared to the younger patients. On the
other hand, less postoperative pain, early activities after
operation may be beneficial for preventing postoperative
complications. However, the data regarding intraoperative
and postoperative complications after colonic resection in
elderly colorectal cancer patients are rare. 
Nowadays, the proportion of elderly colorectal cancer
patients is increasing and is anticipated to increase as life
expectancy increases.(11,12) Thus, we aimed to determine the
safety and feasibility of a laparoscopic colonic resection for
colorectal cancer in patients older than 80 years of age.
Materials and Methods
Patients
Between 1996 and 2010, 10,148 patients were diagnosed
with primary colorectal cancer and among them 9,010 had
curative resection at the Department of Surgery, Samsung
Medical Center (SMC). One hundred ninety two patients
older than 80 years of age (2.1%, 192/9,010) were included
in this study. Laparoscopic resection was performed in 24
(12.4%) of 192 patients, while open resection was
performed in 168 (87.6%) patients. 
There was no case converted from laparoscopic to open
surgery. One patient who had hybrid-laparoscopic surgery
due to additional lateral pelvic lymph node sampling was
included in the laparoscopic group.
Short-term Outcomes of Laparoscopic Colonic Resection in Colorectal 
Cancer Patients Older than 80 Years of Age
80세이상대장암환자에서복강경대장절제술의안전성
성균관대학교의과대학, 삼성서울병원외과학교실 송은진, 김희철, 조용범, 윤성현, 이우용, 전호경
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
Eun Jin Song, Hee Cheol Kim, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee and Ho-Kyung Chun
책임저자 : 김희철
135-710, 서울시강남구일원동50번지성균관대학교삼성서울병원외과
Tel: 02-3410-1655  Fax: 02-3410-6980  E-mail: hckim@skku.edu/hckimcrc@gmail.com
접수일 : 2011년 9월 23일 ; 게재승인일 : 2011년 10월 20일
36 Ban Seok Yang•Seho Park•So Hee Lee•Hyung Seok Park•Hyewon Hwang•Jun Sang Lee•Si Mon Ko•Seung Il Kim•Byeong-Woo Park
Pregnancy-Associated Breast Cancer Compared to
Invasive Ductal Carcinoma Less Than 40 Year-Old of Age
1Department of Surgery, 2Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Ban Seok Yang,1 Seho Park,1 So Hee Lee,1 Hyung Seok Park,1 Hyewon Hwang,1 Jun Sang Lee,1 Si Mon Ko,1
Seung Il Kim,1 and Byeong-Woo Park1,2
Abstract
Purpose : The aims of this study were to investigate clinicopathological characteristics and outcomes of
pregnancy-associated breast cancer (PABC) and to determine the implications of pregnancy itself on the prognosis
of PABC. 
Methods : Clinicopathological features, treatment patterns, and survival of 14 PABC patients were compared to
those of 855 invasive ductal carcinoma (IDC) patients under 40 years of age, who were treated between 1987 and
2007, using a chi-square test, the Kaplan-Meier method, and Cox’s hazards models. PABC was defined as breast
cancer diagnosed during pregnancy or within the first year after delivery. 
Results : Among 14 PABCs, 7 were diagnosed during pregnancy and 7, during the first postpartum year. The mean
duration of the symptoms was 7.6 months. The mean age at diagnosis of PABC and IDC under 40 years was 32.6
and 34.6 years, respectively (p=0.044). All PABCs were ductal type. Hormone receptors, treatment modalities, and
tumor and node stage were not statistically different between PABC and IDC under 40 years. Five-year disease-
free, locoregional relapse-free, distant relapse-free, and overall survival of PABC was 57.1%, 71.3%, 56.4%, and
70.0%, respectively. Survival was not significantly different between two groups. In Cox°Øs models, PABC was not
associated with survival outcomes. Among PABCs, there was no statistical difference in survival between patients
diagnosed before and after delivery. 
Conclusion : Pregnancy itself does not increase the risk of poorer outcomes among young breast cancer patients.
Vigilant diagnosis and multidisciplinary treatment should be recommended to best manage woman with PABC
and her baby.
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